LV10269B - Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use - Google Patents

Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use Download PDF

Info

Publication number
LV10269B
LV10269B LVP-93-820A LV930820A LV10269B LV 10269 B LV10269 B LV 10269B LV 930820 A LV930820 A LV 930820A LV 10269 B LV10269 B LV 10269B
Authority
LV
Latvia
Prior art keywords
methyl
compound
pyridinyl
benzimidazole
preparation
Prior art date
Application number
LVP-93-820A
Other languages
English (en)
Other versions
LV10269A (lv
Inventor
Brandstrim Arne Elof
Lindberg Per Lennart
Sunden Gunnel Elisabeth
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9002206A external-priority patent/SE9002206D0/xx
Priority claimed from SE9002207A external-priority patent/SE9002207D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of LV10269A publication Critical patent/LV10269A/lv
Publication of LV10269B publication Critical patent/LV10269B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Claims (16)

  1. LV 10269 Izgudrojuma formula 1. Savienojumi ar formulu (I) OR*
    un to fizioloģiski pieņemamās sālis, kur: R1 un R2 ir dažādi un katrs no tiem var būt H, C^.alkilgrupa, -CO-R5, kur R5 ir CM.alkilgrupa, CM.alkoksigrupa, pie tam viens no R1 vai R2 vienmēr ir grupa -CO-R5; R3 un R4 ir vienādi vai dažādi un ņemti no grupas: -CH3, -C2HS, un -CH2CH2OCH3, vai 1 R3 un R4 kopā ar blakusesošajiem, pie piridīna gredzena saistītajiem skābekļa atomiem, un piridīna gredzena oglekļa atomiem veido ciklu, kurā daļai, ko veido R3 un R4 atbilst grupa: -CH2 CH2 CH2-, -CH2 CH2- vai -CH2-.
  2. 2. Savienojums pēc punkta 1, proti, 5-karbometoksi-6-metil-2-{[(3,4-dimetoksi-2-pīridinil)metiI]suIfinil}-1 H-benzimidazols.
  3. 3. Savienojums pēc punkta 1, proti, 5-acetilmetil-2-{[(3,4-dimetoksi-2-pīridinil)metil]sulfinil}-1 H-benzimīdazols.
  4. 4. Savienojums pēc punkta 1, proti, 5-acetil-6-metil- 2-{[(3,4-propilēndioksi-2-piridinil)metil]sulfinilļ-1H-benzimidazols.
  5. 5. Savienojums pēc punkta 1, proti, 5-acetil-6-metil- 2-{[(3,4-metilēndioksi-2-piridinil)metilļsulfinil}-1H-benzimidazols.
  6. 6. Savienojums pēc punkta 1 nātrija sāls veidā.
  7. 7. Savienojums pēc punkta 3 nātrija sāls veidā.
  8. 8. Savienojums pēc punkta 1 magnija sāls veidā.
  9. 9. Farmaceitiskā kompozīcija , kas kā aktīvo vielu satur savienojumu pēc punkta 1.
  10. 10. Savienojuma pēc punkta 1 pielietojums ārstniecības līdzekļu ražošanā.
  11. 11. Savienojuma pēc punkta 1 pielietojums tādu ārstniecības līdzekļu ražošanā, kas paredzēti kuņģa skābes izdalīšanās nomākšanai zīdītājos, ieskaitot cilvēku. 2 LV10269
  12. 12. Savienojuma pēc punkta 1 pielietojums tādu ārstniecības līdzekļu ražošanā, kas paredzēti kuņģa un zarnu trakta iekaisuma slimību ārstēšanai zīdītājos, ieskaitot cilvēku.
  13. 13. Savienojuma pēc punkta 1 pielietojums kuņģa skābes izdalīšanās nomākšanai zīdītājos, ieskaitot cilvēku.
  14. 14. Savienojuma pēc punkta 1 pielietojums kuņģa un zarnu trakta iekaisuma slimību ārstēšanai zīdītājos, ieskaitot cilvēku.
  15. 15. Paņēmiens savienojuma ar formulu (I) pēc punkta 1 iegūšanai, kas a t š ķ i r a s ar to, ka: oksidē savienojumu ar formulu (II): OR4
    (II) kurā R1, R2 , R3 un R4 nozīmes jau minētas formulā (I).
  16. 16. Jauni starpprodukti, proti: - 2-metil-3,4-propilēndioksipiridīns, - 2-oksimetil-3,4-propilēndioksipiridīns, - 2-metil-3,4-metilēndioksipiridīns, - 2-oksimetil-3,4-metilēndioksipiridīns, - 5-acetil-6-metil-2-{[(3,4-propilēndioksi-2-piridinil)metil]tio}-1H-benzimidazols, - 5-acetil-6-metil-2-{[(3,4-metilēndioksi-2-piridinil)metil]tio}-1 H-benzimidazols, kas paredzēti savienojumu ar formulu (I) pēc punkta 1 iegūšanai. 3
LVP-93-820A 1990-06-20 1993-06-30 Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use LV10269B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9002206A SE9002206D0 (sv) 1990-06-20 1990-06-20 New compounds
SE9002207A SE9002207D0 (sv) 1990-06-20 1990-06-20 New compounds i
PCT/SE1991/000416 WO1991019712A1 (en) 1990-06-20 1991-06-11 Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use

Publications (2)

Publication Number Publication Date
LV10269A LV10269A (lv) 1994-10-20
LV10269B true LV10269B (en) 1995-10-20

Family

ID=26660803

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-820A LV10269B (en) 1990-06-20 1993-06-30 Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use

Country Status (28)

Country Link
US (1) US5430042A (lv)
EP (1) EP0593463B1 (lv)
JP (1) JP3049367B2 (lv)
CN (1) CN1058213A (lv)
AP (1) AP253A (lv)
AT (1) ATE184602T1 (lv)
AU (1) AU649456B2 (lv)
CA (1) CA2083606C (lv)
CZ (1) CZ279434B6 (lv)
DE (1) DE69131627T2 (lv)
EG (1) EG19752A (lv)
ES (1) ES2140391T3 (lv)
FI (1) FI925767A0 (lv)
HU (1) HUT62882A (lv)
IE (1) IE912026A1 (lv)
IL (1) IL98472A (lv)
IS (1) IS3720A7 (lv)
LV (1) LV10269B (lv)
MA (1) MA22198A1 (lv)
NO (1) NO924650D0 (lv)
NZ (1) NZ238545A (lv)
OA (1) OA09683A (lv)
PL (2) PL165898B1 (lv)
PT (1) PT98036A (lv)
RO (1) RO110497B1 (lv)
TN (1) TNSN91050A1 (lv)
WO (1) WO1991019712A1 (lv)
YU (1) YU104091A (lv)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103776D0 (sv) * 1991-12-19 1991-12-19 Astra Ab New compounds
TNSN95062A1 (fr) * 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DK0723436T3 (da) * 1994-07-08 2001-11-26 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5545661A (en) * 1995-05-16 1996-08-13 Eli Lilly And Company Methods for inhibiting bone loss with bis-pyrone oxovanadium compounds
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
WO1998054172A1 (en) * 1997-05-30 1998-12-03 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
WO1999002521A1 (fr) * 1997-07-11 1999-01-21 Eisai Co., Ltd. Procedes d'elaboration de derives pyridiniques
GB9805558D0 (en) * 1998-03-17 1998-05-13 Knoll Ag Chemical process`
HUP0103464A3 (en) * 1998-08-10 2002-11-28 U S Government Represented By Prodrugs of proton pump inhibitors and pharmaceutical compositions containing them
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
AU2003246792B2 (en) 2002-04-09 2008-08-28 Flamel Ireland Limited Oral suspension of active principle microcapsules
NZ538221A (en) * 2002-07-19 2006-11-30 Univ California Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor for treating gastrointestinal inflammatory diseases
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
TW200606163A (en) * 2004-04-22 2006-02-16 Eisai Co Ltd Imidazopyridine compound
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EP1775292B1 (en) * 2004-08-06 2012-06-27 Eisai R&D Management Co., Ltd. Salts of benzimidazole derivative with amines and process for production thereof
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
WO2007122686A1 (ja) * 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
DK2046334T3 (da) 2006-07-25 2014-08-25 Vecta Ltd Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5492417B2 (ja) 2006-10-13 2014-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 胃酸分泌抑制作用を有するベンズイミダゾール化合物
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2716367C (en) 2008-02-20 2015-05-26 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
AU568441B2 (en) * 1984-09-24 1987-12-24 Upjohn Company, The 2-(pyridylalkenesulfinyl) benzimidazole derivatives
IL76839A (en) * 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
SE8500996D0 (sv) * 1985-03-01 1985-03-01 Haessle Ab Method of treatment
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3722810A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Substituierte benzimidazole, verfahren zu deren herstellung, diese enthaltende pharmazeutische zubereitungen und deren verwendung
HU886738D0 (en) * 1987-10-30 1990-02-28 Haessle Ab Process for the preparation of pharmaceutical compositions against osteoporosis containing 2-pyridinyl-methyl-(sulfinyl or thio)-benzimidazoles
AU2817989A (en) * 1987-12-11 1989-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel benzimidazole derivatives
EP0415990A1 (de) * 1988-05-25 1991-03-13 Byk Gulden Lomberg Chemische Fabrik GmbH Neue fluoralkoxyverbindungen
SE8804628D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New compounds
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles

Also Published As

Publication number Publication date
IL98472A (en) 1995-08-31
PL297294A1 (lv) 1992-07-13
JP3049367B2 (ja) 2000-06-05
IL98472A0 (en) 1992-07-15
YU104091A (sh) 1994-01-20
WO1991019712A1 (en) 1991-12-26
NO924650L (no) 1992-12-02
EG19752A (en) 1996-01-31
US5430042A (en) 1995-07-04
AP253A (en) 1993-05-03
CS189391A3 (en) 1992-06-17
DE69131627T2 (de) 2000-04-27
EP0593463A1 (en) 1994-04-27
ES2140391T3 (es) 2000-03-01
FI925767A (fi) 1992-12-18
HU9204034D0 (en) 1993-03-29
MA22198A1 (fr) 1992-04-01
PT98036A (pt) 1992-03-31
DE69131627D1 (de) 1999-10-21
IE912026A1 (en) 1992-01-01
FI925767A0 (fi) 1992-12-18
LV10269A (lv) 1994-10-20
RO110497B1 (ro) 1996-01-30
CN1058213A (zh) 1992-01-29
PL165898B1 (pl) 1995-02-28
AU8061791A (en) 1992-01-07
TNSN91050A1 (fr) 1992-10-25
PL297295A1 (lv) 1992-07-13
CA2083606C (en) 2001-08-21
CZ279434B6 (cs) 1995-04-12
NO924650D0 (no) 1992-12-02
PL166209B1 (pl) 1995-04-28
NZ238545A (en) 1993-08-26
ATE184602T1 (de) 1999-10-15
OA09683A (en) 1993-05-15
JPH05507714A (ja) 1993-11-04
EP0593463B1 (en) 1999-09-15
CA2083606A1 (en) 1991-12-21
IS3720A7 (is) 1991-12-21
AU649456B2 (en) 1994-05-26
HUT62882A (en) 1993-06-28
AP9100286A0 (en) 1991-07-31

Similar Documents

Publication Publication Date Title
LV10269B (en) Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
US5008278A (en) Therapeutically active compound and a process for its preparation
AP215A (en) Substituted benzimidazoles, process for their preparation and their pharmaceutical use.
AU636866B2 (en) Therapeutically active substituted benzimidazole and process for its preparation
US5025024A (en) Therapeutically active fluoro-substituted compound